ArticleJournal of the Endocrine Society2026
Allopurinol has no effect on calcitriol or other CKD-MBD biomarkers: a randomized double-blind study.
Article in Journal of the Endocrine Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: New evidence has emerged linking uric acid levels to Chronic Kidney Disease and Mineral and Bone Disorder (CKD-MBD). However, interventional studies remain scarce. We evaluated the effect of allopurinol on CKD-MBD biomarkers. Methods: This is a randomized, double-blind clinical trial involving adult patients with stage 3-5 CKD under conservative management. Participants received either allopurinol 300 mg or a placebo for at least 90 days. Clinical data and blood samples were collected at baseline and at the end of the follow-up period to assess changes in calcium, phosphate, 25-hydroxyvitamin-D, parathyroid hormone (PTH), 1,25-hydroxyvitamin D, fibroblast growth factor 23 (FGF23), α Klotho, and bone alkaline phosphatase. Results: Forty-nine patients completed the study (25 in the allopurinol group and 24 in the placebo group). Most participants were women (53.1%), with a mean age of 71 ± 11 years and an average eGFR of 27.8 ± 11.0 mL/min/1.73 m Conclusion: Despite its urate-lowering effect, allopurinol did not produce meaningful changes in the major CKD-MBD biomarkers over the study period. Our results strengthen existing recommendations to restrict uric acid-lowering treatment to symptomatic gout, as we did not identify any associated improvements in mineral metabolism.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.